Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1326139 | 1.00 | PDE5A (0.85) | PDE5A | |
| SCHEMBL1326138 | 1.00 | PDE5A (0.85) | PDE5A | |
| SCHEMBL6784109 | 0.94 | PDE5A (0.86) | PDE5A | |
| SCHEMBL7714898 | 0.94 | PDE5A (0.86) | PDE5A | |
| SCHEMBL7714894 | 0.94 | PDE5A (0.86) | PDE5A | |
| SCHEMBL7433397 | 0.92 | PDE5A (0.84) | PDE5A | |
| SCHEMBL6782147 | 0.92 | PDE5A (0.84) | PDE5A | |
| SCHEMBL7683497 | 0.92 | PDE5A (0.84) | PDE5A | |
| SCHEMBL7683504 | 0.92 | PDE5A (0.84) | PDE5A | |
| SCHEMBL6782139 | 0.92 | PDE5A (0.84) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179701-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-06-26 | — | — | US | claimed |
| EP-2556820-A2 | COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES | SK Chemicals, Co., Ltd. (KR) | 2013-02-13 | — | — | EP | claimed |
| US-20130030174-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-01-31 | — | — | US | claimed |
| EP-2327408-A1 | Tetracyclic cyclic gmp-specific phosphodiesterase inhibitors for the treatment of benign prostatic hypertrophy | ICOS Corporation (US) | 2011-06-01 | — | — | EP | claimed |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | ICOS CORPORATION | 2002-08-29 | — | — | US | claimed |
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | claimed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| US-6140329-A | FOR TREATING A MALE ANIMAL FOR ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-10-31 | — | — | US | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | claimed |
| US-9943398-B2 | Increasing survival of free tissue grafts and flaps using phosphodiesterase type 5 (PDE5) inhibitors | NEW YORK UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9155691-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2015-10-13 | — | — | US | disclosed |
| US-20140179701-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-20140128405-A1 | Composition and use for phosphodiesterase inhibitors | CHERVINSKY ALEX (US) | 2014-05-08 | — | — | US | disclosed |
| US-8716298-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2014-05-06 | — | — | US | disclosed |
| US-6140329-A | FOR TREATING A MALE ANIMAL FOR ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-10-31 | — | — | US | disclosed |
| US-6127542-A | CHEMICAL INTERMEDIATES TO SPECIFIED PYRAZINO(2',1':6,1)PYRIDO(3,4B)INDOLE-1,4-DIONES WHICH ARE SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE; TO TREAT CARDIOVASCULAR DISORDERS | ICOS CORPORATION (US) | 2000-10-03 | — | — | US | disclosed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | disclosed |
| US-6025494-A | CYCLIZATION OF DICARBONYL-SUBSTITUTED PYRIDOINDOLES YIELDS PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0740668-B1 | TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE | ICOS CORP (US) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | MKI67, PNPO, CDK4 | PDE5A 4371/4885 |
| US-20020119976-A1 | Tetracyclic derivatives, process of preparation and use | PDE3A, PDE3B, PDE2A | PDE5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.